Generic & Biosimilar Medicines Southern Africa
Who are we?
The Generic and Biosimilar Medicines of Southern Africa was formerly the National Association of Pharmaceutical Manufacturers (NAPM) which originated as a Section 21 Trade Association in 1977. It was incorporated as a not for profit company (NPC) in terms of the amendment to the Companies Act of 2008.
It is a voluntary consisting of South African and Generics based Pharmaceutical manufacturers and distributors. Some of GBM’s function is to ensure that the sector plays a constructive role in our country’s economic growth, development and transformation and thereby create an environment in which the sector can thrive, expand, be competitive and enhance access of medicines to all of our country’s citizens.
GBM supports Government’s initiative of Accelerated Shared Growth Initiative SA (ASGISA) and in particular shared growth to address the twin challenges of unemployment and poverty alleviation and the economic growth rate required to meet these two challenges. NAPM is a full member of the IGBA and SAGMA.
Our mission and vision
We aim to champion affordable and accessible healthcare by promoting generic and biosimilar medicines and supporting the development of the South African pharmaceutical industry as a national asset. We also aim to contribute to the efficiency of the regulatory system which will in turn help speed up the registration of drugs.
Our Executive Committee
Melinda Badenhorst (Novagen Pharma)
Desmond Brothers –Immediate past Chairperson
Muhammad Bodhania (Oethmaan Biosims)
Suhail Gani (Austell Laboratories)
Lorraine Keyser (Dr Reddys) – Vice Chairperson
Herman Grobler (Cipla) – Chairperson
Reshlan Nagoor (Accord Healthcare)
Mervin Naidoo (Mylan)
Erik Roos (Pharmadynamics)
Vineet Shiva (Zydus)
Anita Smal (Abex)
Guillaume Van Niekerk (Litha Healthcare)
Vivian Frittelli (GBM) –CEO
The benefits of being a member
The strength of any voluntary is dependent on the contribution of its members. The overriding mission of the GBM is to “provide greater access to medicines for patients in Southern Africa”. Our members ,as providers of those medicines benefit through our generic and biosmilar medicines awareness efforts, lobbying with regulators, representation on inter- governmental bodies and relationships with international associations.
Specific benefits encompass:-
Science / Regulatory/ Biosimilars Committee
Trade and Industry / Tenders Committee
Intellectual Property Committee
Pricing /Market Access Committee